0.6225

0.47% 0.0029

InspireMD Inc. (NSPR)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$0.6196

Offen:

$0.622

24-Stunden-Volumen:

65,699

Relative Volume:

0.89

Marktkapitalisierung:

$29.16M

Einnahmen:

$10.85M

Nettoeinkommen (Verlust:

$-51.31M

KGV:

-0.8446

EPS:

-0.737

Netto-Cashflow:

$-40.15M

1W Leistung:

-11.07%

1M Leistung:

-25.91%

6M Leistung:

-59.58%

1J Leistung:

-74.17%

1-Tages-Spanne:

$0.609

$0.63

1-Wochen-Bereich:

$0.60

$0.71

52-Wochen-Spanne:

$0.60

$2.565

InspireMD Inc. Stock (NSPR) Company Profile

Firmenname

InspireMD Inc.

Sektor

Healthcare (1064)

Branche

Medical Devices (138)

Telefon

972 3 6917691

Adresse

4 Menorat Hamaor Street, Tel Aviv

Mitarbeiter

Twitter

@InspireMD

Nächster Verdiensttermin

2026-11-03

Neueste SEC-Einreichungen

NSPR's Discussions on Twitter

Compare NSPR vs ABT, MDT, SYK, BSX, EW

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NSPR InspireMD Inc.	0.6225	32.79M	10.85M	-51.31M	-40.15M	-0.737
ABT Abbott Laboratories	97.50	168.71B	46.59B	5.41B	7.38B	3.0938
MDT Medtronic Plc	86.38	113.38B	36.36B	4.84B	5.43B	3.7261
SYK Stryker Corp	275.43	104.47B	25.27B	3.34B	4.57B	8.6334
BSX Boston Scientific Corp	42.60	63.65B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	85.15	49.74B	6.30B	1.07B	1.09B	1.8406

InspireMD Inc. Stock (NSPR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-02	Eingeleitet	Maxim Group	Buy
2016-01-07	Eingeleitet	Rodman & Renshaw	Buy
2015-03-13	Herabstufung	Oppenheimer	Outperform → Perform
2013-11-26	Eingeleitet	Oppenheimer	Outperform

InspireMD Inc. Aktie (NSPR) Neueste Nachrichten

Oct 01, 2026

Director Stuka Paul reports acquiring and disposing of two warrant series at InspireMD (NSPR). - Stock Titan

Sep 23, 2026

InspireMD (NSPR) director Gary S. Roubin acquired and disposed of warrants with different exercise prices. - Stock Titan

Sep 23, 2026

InspireMD (NSPR) director Michael Berman reports acquiring and disposing of warrants at two exercise prices. - Stock Titan

Sep 23, 2026

Sep 22, 2026

InspireMD amends certain Series J, Series K warrants - Medical Buyer

Sep 22, 2026

Lake Street Maintains InspireMD(NSPR.US) With Buy Rating, Maintains Target Price $4 - Moomoo

Sep 22, 2026

Sep 21, 2026

InspireMD (NASDAQ: NSPR) Revises Series J and K Warrants with $0.7674 Exercise Price and FDA-Linked Expiry by May 2028 - Kalkine Media

Sep 21, 2026

InspireMD Amends Warrants for Up to $11 Million Tied to FDA Approval - Minichart

Sep 21, 2026

InspireMD amends warrants tied to FDA approval timeline By Investing.com - Investing.com South Africa

Sep 21, 2026

InspireMD Amends Warrants to Support CGuard Prime Launch - TipRanks

Sep 21, 2026

InspireMD amends warrants tied to FDA approval timeline - Investing.com

Sep 21, 2026

InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million - The Manila Times

Sep 21, 2026

An anticipated FDA approval could open up $11 million for InspireMD's stroke-prevention device. - Stock Titan

Sep 21, 2026

Sep 17, 2026

InspireMD Q2FY26 Results: Net loss widens to $14.3M on recall impact - scanx.trade

Sep 17, 2026

Full Transcript: InspireMD Q2 2026 Earnings Call - Benzinga

Sep 17, 2026

Sep 14, 2026

NSPR: Innovative carotid stent technology is set to disrupt a rapidly expanding U.S. vascular market - TradingView

Sep 14, 2026

Sep 07, 2026

InspireMD announces inducement grants - Medical Buyer

Sep 07, 2026

Sep 05, 2026

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Sep 05, 2026

Sep 04, 2026